{"title":"Look out for the white lesions in DOCK-8 (c. 5963 c>t) immunodeficiency – A novel mutation","authors":"R. Ahuja, Ritu Sharma, Sudheer Arava, N. Bhari","doi":"10.25259/ijdvl_503_2024","DOIUrl":"https://doi.org/10.25259/ijdvl_503_2024","url":null,"abstract":"","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141695736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association between atopy and leprosy: Overestimated or real?","authors":"Neel Prabha, Meghana P S Reddy","doi":"10.25259/ijdvl_612_2024","DOIUrl":"https://doi.org/10.25259/ijdvl_612_2024","url":null,"abstract":"","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141364300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seung-Ah Yoo, Marianne Isabel A. Sayo, Ji Hyun Lee
Several studies have reported that psoriasis has a positive correlation with type 2 diabetes mellitus (DM). Understanding the risk of psoriasis in diabetic patients is significant because it allows for early intervention and potential insights into the common pathways between the two conditions. We analysed the risk of psoriasis according to the estimated glomerular filtration rate (eGFR) and proteinuria level in DM patients using Korean population–based data. This study was a retrospective cohort study using data collected from the country in the form of exploratory data analysis. A total of 927,234 participants diagnosed with DM were enrolled. Patients under the age of 20 with existing psoriasis or psoriasis developed within 1 year and missing data were excluded. The development of psoriasis was the primary outcome within a follow-up period of 7.83 ± 1.68 years. Of the 840,395 final participants, 28,010 (3.33%) patients developed psoriasis. In multivariate-adjusted Cox proportional hazards regression models, the DM patients with eGFR < 30 had a higher risk of psoriasis after adjustment (eGFR 60–90, hazard ratio [HR] 1 (Ref.); eGFR < 30, HR 1.173, 95% CI 1.089–1.264). In addition, there was an increased psoriatic risk of patients with DM and proteinuria after adjustment (negative, HR 1 (Ref.); 2+, HR 1.164, 95% CI 1.080–1.254; 3+, HR 1.433, 95% CI 1.273–1.613; 4+, HR 1.508, 95% CI 1.177–1.931). The severity of psoriasis was not measured since the occurrence of psoriasis was the outcome. Details of oral hypoglycaemic agents such as type and dose were not investigated. This study showed that a decrease in eGFR and aggravation of proteinuria increase the risk of psoriasis in diabetic patients. Therefore, by using eGFR and proteinuria as predictive risk factors of psoriasis in DM patients, early and proactive treatment may play a vital role in managing diabetic patients.
多项研究表明，银屑病与 2 型糖尿病（DM）呈正相关。了解糖尿病患者患银屑病的风险意义重大，因为这有助于进行早期干预，并有可能深入了解这两种疾病之间的共同途径。我们利用韩国的人口数据，根据估计的肾小球滤过率（eGFR）和蛋白尿水平分析了糖尿病患者患银屑病的风险。共有 927 234 名确诊为糖尿病的患者参与了这项研究。年龄在 20 岁以下、患有银屑病或在 1 年内出现银屑病以及数据缺失的患者被排除在外。在 840,395 名最终参与者中，28,010 名患者（3.33%）患上了银屑病。在多变量调整后的考克斯比例危险回归模型中，eGFR<30的DM患者在调整后患银屑病的风险更高（eGFR 60-90，危险比[HR]1（参考文献）；eGFR<30，HR 1.173，95% CI 1.089-1.264）。此外，经过调整后，患有糖尿病和蛋白尿的患者患银屑病的风险增加（阴性，HR 1（参考值）；2+，HR 1.164，95% CI 1.080-1.254；3+，HR 1.433，95% CI 1.273-1.613；4+，HR 1.508，95% CI 1.177-1.931）。本研究表明，eGFR 下降和蛋白尿加重会增加糖尿病患者罹患银屑病的风险。因此，将 eGFR 和蛋白尿作为糖尿病患者银屑病的预测风险因素，早期和积极的治疗可在糖尿病患者的管理中发挥重要作用。
{"title":"Association between chronic renal disease and psoriasis risk in diabetes patients: A Korean population-based study","authors":"Seung-Ah Yoo, Marianne Isabel A. Sayo, Ji Hyun Lee","doi":"10.25259/ijdvl_669_2023","DOIUrl":"https://doi.org/10.25259/ijdvl_669_2023","url":null,"abstract":"\u0000\u0000Several studies have reported that psoriasis has a positive correlation with type 2 diabetes mellitus (DM). Understanding the risk of psoriasis in diabetic patients is significant because it allows for early intervention and potential insights into the common pathways between the two conditions.\u0000\u0000\u0000\u0000We analysed the risk of psoriasis according to the estimated glomerular filtration rate (eGFR) and proteinuria level in DM patients using Korean population–based data.\u0000\u0000\u0000\u0000This study was a retrospective cohort study using data collected from the country in the form of exploratory data analysis. A total of 927,234 participants diagnosed with DM were enrolled. Patients under the age of 20 with existing psoriasis or psoriasis developed within 1 year and missing data were excluded. The development of psoriasis was the primary outcome within a follow-up period of 7.83 ± 1.68 years.\u0000\u0000\u0000\u0000Of the 840,395 final participants, 28,010 (3.33%) patients developed psoriasis. In multivariate-adjusted Cox proportional hazards regression models, the DM patients with eGFR < 30 had a higher risk of psoriasis after adjustment (eGFR 60–90, hazard ratio [HR] 1 (Ref.); eGFR < 30, HR 1.173, 95% CI 1.089–1.264). In addition, there was an increased psoriatic risk of patients with DM and proteinuria after adjustment (negative, HR 1 (Ref.); 2+, HR 1.164, 95% CI 1.080–1.254; 3+, HR 1.433, 95% CI 1.273–1.613; 4+, HR 1.508, 95% CI 1.177–1.931).\u0000\u0000\u0000\u0000The severity of psoriasis was not measured since the occurrence of psoriasis was the outcome. Details of oral hypoglycaemic agents such as type and dose were not investigated.\u0000\u0000\u0000\u0000This study showed that a decrease in eGFR and aggravation of proteinuria increase the risk of psoriasis in diabetic patients. Therefore, by using eGFR and proteinuria as predictive risk factors of psoriasis in DM patients, early and proactive treatment may play a vital role in managing diabetic patients.\u0000","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141379912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vishal Gaurav, Gouri Renuka Pushpanandan Anand, S. Khandpur
{"title":"Intradermal naevus with fat: A distinct variant","authors":"Vishal Gaurav, Gouri Renuka Pushpanandan Anand, S. Khandpur","doi":"10.25259/ijdvl_973_2023","DOIUrl":"https://doi.org/10.25259/ijdvl_973_2023","url":null,"abstract":"","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141376813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-06DOI: 10.25259/ijdvl_1268_2023
R. Ahuja, Varniraj Patel, Shivangi Dagar, S. Khandpur
{"title":"An unusual case of benign cutaneous lymphoid hyperplasia masquerading as diffuse Addisonian-like pigmentation with skin infiltration – An atypical presentation","authors":"R. Ahuja, Varniraj Patel, Shivangi Dagar, S. Khandpur","doi":"10.25259/ijdvl_1268_2023","DOIUrl":"https://doi.org/10.25259/ijdvl_1268_2023","url":null,"abstract":"","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141378817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pankaj Das, Anand Mannu, B. Vasudevan, L. P. Krishnan, Silky Priya
{"title":"Erythrodermic scabies in a systemic sclerosis patient","authors":"Pankaj Das, Anand Mannu, B. Vasudevan, L. P. Krishnan, Silky Priya","doi":"10.25259/ijdvl_384_2024","DOIUrl":"https://doi.org/10.25259/ijdvl_384_2024","url":null,"abstract":"","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141379101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-04DOI: 10.25259/ijdvl_1291_2023
He′nan Si, Shanshan Li, Quan Wen, Yan Yu
{"title":"Erythema elevatum diutinum associated with severe ocular complications and lung tuberculosis","authors":"He′nan Si, Shanshan Li, Quan Wen, Yan Yu","doi":"10.25259/ijdvl_1291_2023","DOIUrl":"https://doi.org/10.25259/ijdvl_1291_2023","url":null,"abstract":"","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141388113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors are novel treatments for moderate-to-severe plaque psoriasis. To perform a network meta-analysis to compare the efficacy and safety of TYK2 inhibitors with other oral drugs in moderate-to-severe psoriasis. Eligible randomised clinical trials (RCTs) were identified from public databases (published before November 2, 2023). Random-effect frequentist network meta-analysis was performed with ranking based on the surface under the cumulative ranking curve (SUCRA) of Physician’s Global Assessment of “clear” or “almost clear” (PGA 0/1), 75% reduction from baseline in Psoriasis Area and Severity Index (PASI-75). Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included. Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12– 16 weeks. Tofacitinib (10 mg BID) was considered the most unsafe. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment. Insufficiency of eligible data and no long-term follow-up data. Deucravacitinib showed superior efficacy and safety for treating moderate-to-severe psoriasis over other included drugs.
{"title":"Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis","authors":"Yaxuan Zheng, Yue Han, Jincong Chen, Jiahao Huang, Changhua Zhu, Lihang Lin, Huichun Su","doi":"10.25259/ijdvl_775_2023","DOIUrl":"https://doi.org/10.25259/ijdvl_775_2023","url":null,"abstract":"\u0000\u0000Janus kinase (JAK)/tyrosine kinase 2 (TYK2) inhibitors are novel treatments for moderate-to-severe plaque psoriasis.\u0000\u0000\u0000\u0000To perform a network meta-analysis to compare the efficacy and safety of TYK2 inhibitors with other oral drugs in moderate-to-severe psoriasis.\u0000\u0000\u0000\u0000Eligible randomised clinical trials (RCTs) were identified from public databases (published before November 2, 2023). Random-effect frequentist network meta-analysis was performed with ranking based on the surface under the cumulative ranking curve (SUCRA) of Physician’s Global Assessment of “clear” or “almost clear” (PGA 0/1), 75% reduction from baseline in Psoriasis Area and Severity Index (PASI-75).\u0000\u0000\u0000\u0000Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included. Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12– 16 weeks. Tofacitinib (10 mg BID) was considered the most unsafe. Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment.\u0000Analysis of Ranking according to efficacy and safety showed deucravacitinib (3 mg QD and 3 mg BID) was the best treatment.\u0000\u0000\u0000\u0000Insufficiency of eligible data and no long-term follow-up data.\u0000\u0000\u0000\u0000Deucravacitinib showed superior efficacy and safety for treating moderate-to-severe psoriasis over other included drugs.\u0000","PeriodicalId":513160,"journal":{"name":"Indian Journal of Dermatology, Venereology and Leprology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141271035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：